Display options
Cite
Kurena B, Müller E, Christopoulos PF, et al. Generation and Functional . Front Immunol. 2017;8:1667doi: 10.3389/fimmu.2017.01667.
Kurena, B., Müller, E., Christopoulos, P. F., Johnsen, I. B., Stankovic, B., Øynebråten, I., Corthay, A., & Zajakina, A. (2017). Generation and Functional . Frontiers in immunology, 81667. https://doi.org/10.3389/fimmu.2017.01667
Kurena, Baiba, et al. "Generation and Functional ." Frontiers in immunology vol. 8 (2017): 1667. doi: https://doi.org/10.3389/fimmu.2017.01667
Kurena B, Müller E, Christopoulos PF, Johnsen IB, Stankovic B, Øynebråten I, Corthay A, Zajakina A. Generation and Functional . Front Immunol. 2017 Nov 30;8:1667. doi: 10.3389/fimmu.2017.01667. eCollection 2017. PMID: 29276511; PMCID: PMC5727424.
Copy Download .nbib Format: NLM
Share it on

Front Immunol. 2017 Nov 30;8:1667. doi: 10.3389/fimmu.2017.01667. eCollection 2017.

Generation and Functional .

Frontiers in immunology

Baiba Kurena, Elisabeth Müller, Panagiotis F Christopoulos, Ingvild Bjellmo Johnsen, Branislava Stankovic, Inger Øynebråten, Alexandre Corthay, Anna Zajakina

Affiliations

  1. Tumor Immunology Lab, Department of Pathology, Rikshospitalet, Oslo University Hospital, University of Oslo, Oslo, Norway.
  2. Cancer Gene Therapy Group, Latvian Biomedical Research and Study Centre, Riga, Latvia.
  3. Department of Biosciences, University of Oslo, Oslo, Norway.
  4. Department of Laboratory Medicine, Norwegian University of Science and Technology, Trondheim, Norway.

PMID: 29276511 PMCID: PMC5727424 DOI: 10.3389/fimmu.2017.01667

Abstract

Cytokine gene delivery by viral vectors is a promising novel strategy for cancer immunotherapy. Semliki Forest virus (SFV) has many advantages as a delivery vector, including the ability to (i) induce p53-independent killing of tumor cells

Keywords: Lewis lung carcinoma; Semliki Forest virus; cancer immunotherapy; cytokines; gene delivery; macrophage activation

References

  1. Oncoimmunology. 2015 Jul 25;5(1):e1039763 - PubMed
  2. J Immunol. 2014 Nov 1;193(9):4722-31 - PubMed
  3. J Immunol. 1988 Oct 15;141(8):2629-34 - PubMed
  4. J Gen Virol. 2004 Nov;85(Pt 11):3343-51 - PubMed
  5. Methods Mol Biol. 2005;290:91-103 - PubMed
  6. Vaccine. 2003 Mar 7;21(11-12):1082-8 - PubMed
  7. Gene Ther. 2001 Feb;8(4):300-7 - PubMed
  8. J Immunol. 1983 May;130(5):2011-3 - PubMed
  9. Gene Ther. 1999 Oct;6(10):1728-33 - PubMed
  10. Future Microbiol. 2009 Sep;4(7):837-56 - PubMed
  11. EMBO J. 2002 Oct 1;21(19):5141-50 - PubMed
  12. Mol Ther. 2005 Jul;12(1):153-63 - PubMed
  13. Adv Exp Med Biol. 2007;590:195-208 - PubMed
  14. Nat Rev Mol Cell Biol. 2010 Oct;11(10):700-14 - PubMed
  15. Cancer Res. 1988 Apr 15;48(8):2179-83 - PubMed
  16. J Neurovirol. 2003 Feb;9(1):1-15 - PubMed
  17. Cell Death Dis. 2011 Nov 17;2:e230 - PubMed
  18. Proc Natl Acad Sci U S A. 1983 Jun;80(12):3782-6 - PubMed
  19. Neurosurg Focus. 2000 Dec 15;9(6):e7 - PubMed
  20. Int J Cancer. 1993 Mar 12;53(5):829-36 - PubMed
  21. Biochem Biophys Res Commun. 1988 Nov 30;157(1):87-94 - PubMed
  22. Cell. 1988 Apr 8;53(1):45-53 - PubMed
  23. Int J Cancer. 1986 Nov 15;38(5):763-9 - PubMed
  24. Proc Natl Acad Sci U S A. 2016 Feb 23;113(8):2223-8 - PubMed
  25. Microbiol Rev. 1994 Sep;58(3):491-562 - PubMed
  26. Cell. 2010 Mar 19;140(6):883-99 - PubMed
  27. Biotechnology (N Y). 1994 Nov;12(11):1127-31 - PubMed
  28. Proc Natl Acad Sci U S A. 2012 May 15;109(20):7841-6 - PubMed
  29. Eur Respir J. 2009 Jan;33(1):118-26 - PubMed
  30. Cancer Chemother Pharmacol. 1986;18(1):63-8 - PubMed
  31. Biotechnology (N Y). 1991 Dec;9(12):1356-61 - PubMed
  32. BMC Cancer. 2010 Mar 25;10:112 - PubMed
  33. Oncol Rep. 2006 Oct;16(4):713-9 - PubMed
  34. CSH Protoc. 2008 Dec 01;2008:pdb.prot5080 - PubMed
  35. J Immunol. 2013 Mar 15;190(6):2994-3004 - PubMed
  36. J Interferon Cytokine Res. 1998 Apr;18(4):263-71 - PubMed
  37. J Gen Virol. 1977 Feb;34(2):353-61 - PubMed
  38. Nat Commun. 2011;2:240 - PubMed
  39. Int J Cancer. 2009 Jul 15;125(2):367-73 - PubMed
  40. Biochem Biophys Res Commun. 2011 Aug 5;411(3):569-73 - PubMed
  41. Sci Rep. 2015 Sep 24;5:14273 - PubMed
  42. Br J Cancer. 2000 Mar;82(5):1000-3 - PubMed
  43. Nature. 1998 Mar 5;392(6671):86-9 - PubMed
  44. Gene Ther. 2012 Mar;19(3):271-8 - PubMed
  45. Cancer Res. 2015 Feb 1;75(3):497-507 - PubMed
  46. Nature. 1985 Dec 19-1986 Jan 1;318(6047):665-7 - PubMed
  47. Mol Cancer Res. 2014 Jan;12(1):3-13 - PubMed
  48. Ann Surg Oncol. 1997 Jan;4(1):64-9 - PubMed
  49. Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7556-61 - PubMed
  50. J Virol. 2009 Dec;83(23 ):12266-78 - PubMed
  51. Immunity. 2000 Jun;12(6):677-86 - PubMed
  52. Nat Med. 2005 Nov;11(11):1180-7 - PubMed
  53. Oncoimmunology. 2012 Oct 1;1(7):1146-1155 - PubMed
  54. J Immunol. 1986 Apr 1;136(7):2445-50 - PubMed
  55. Nat Med. 1998 Apr;4(4):408-14 - PubMed
  56. Cancer Res. 1986 Aug;46(8):3990-3 - PubMed
  57. Cancer Gene Ther. 2001 Oct;8(10):796-802 - PubMed
  58. Hum Gene Ther. 2014 Feb;25(2):132-43 - PubMed
  59. Science. 1987 Jan 23;235(4787):473-6 - PubMed
  60. Virus Res. 2008 Jan;131(1):54-64 - PubMed
  61. J Clin Oncol. 1992 Jan;10(1):52-60 - PubMed
  62. Nature. 1997 Feb 20;385(6618):729-33 - PubMed
  63. Eur J Cancer. 2006 Apr;42(6):717-27 - PubMed
  64. J Cell Physiol. 1983 Nov;117(2):189-94 - PubMed
  65. Cancer Res. 2005 Apr 15;65(8):3437-46 - PubMed
  66. Gene Ther. 2000 Sep;7(17):1477-82 - PubMed
  67. Oncotarget. 2011 Oct;2(10):739-51 - PubMed
  68. J Exp Med. 1998 May 4;187(9):1477-85 - PubMed
  69. Immunity. 2005 Mar;22(3):371-83 - PubMed
  70. Immunity. 1994 Sep;1(6):447-56 - PubMed
  71. Proc Natl Acad Sci U S A. 1975 Sep;72(9):3666-70 - PubMed
  72. Cytokine. 1999 Oct;11(10):773-82 - PubMed
  73. J Gen Virol. 1998 Oct;79 ( Pt 10):2405-10 - PubMed
  74. Cell Immunol. 1988 Oct 1;116(1):112-22 - PubMed
  75. Gene Ther. 2000 Nov;7(21):1859-66 - PubMed
  76. J Immunopharmacol. 1986;8(1):89-97 - PubMed
  77. Cancer Res. 1987 Nov 15;47(22):5868-74 - PubMed
  78. Cancer Res. 2006 Feb 1;66(3):1620-9 - PubMed
  79. Cancer Res. 1984 Sep;44(9):4164-71 - PubMed
  80. Proc Natl Acad Sci U S A. 1993 Apr 1;90(7):2774-8 - PubMed
  81. Nat Med. 1999 Jul;5(7):823-7 - PubMed
  82. Br J Cancer. 2000 Feb;82(4):973-80 - PubMed
  83. BMC Cancer. 2014 Jun 20;14:460 - PubMed
  84. Cancer Res. 1988 Oct 15;48(20):5818-24 - PubMed
  85. Int J Cancer. 2002 Apr 1;98(4):554-60 - PubMed
  86. PLoS One. 2013 Jun 25;8(6):e65896 - PubMed
  87. Cancer Res. 2003 Jul 15;63(14):4095-100 - PubMed
  88. Cancer Res. 2006 Jul 15;66(14):7185-94 - PubMed
  89. J Virol. 1997 Feb;71(2):1583-90 - PubMed
  90. Blood. 2002 Sep 1;100(5):1728-33 - PubMed
  91. Nature. 2001 Apr 26;410(6832):1107-11 - PubMed
  92. Front Immunol. 2017 Oct 26;8:1383 - PubMed
  93. Int J Mol Med. 2000 Mar;5(3):241-5 - PubMed
  94. J Immunol. 1983 Aug;131(2):826-32 - PubMed
  95. Gene Ther. 1999 Apr;6(4):606-15 - PubMed
  96. Apoptosis. 2004 Jul;9(4):495-500 - PubMed
  97. Cancer Gene Ther. 2012 Aug;19(8):579-87 - PubMed
  98. Gene Ther. 2005 Aug;12(16):1253-63 - PubMed
  99. J Immunol. 2000 Jun 15;164(12):6166-73 - PubMed

Publication Types